

# World Journal of *Gastrointestinal Pharmacology and Therapeutics*

*World J Gastrointest Pharmacol Ther* 2022 July 5; 13(4): 33-66





**MINIREVIEWS**

- 33 Biliary atresia and congenital disorders of the extrahepatic bile ducts  
*Islek A, Tungor G*

**ORIGINAL ARTICLE**

**Observational Study**

- 47 Primary hyperparathyroidism presenting as acute pancreatitis: An institutional experience with review of the literature  
*Rashmi KG, Kamalanathan S, Sahoo J, Naik D, Mohan P, Pottakkat B, Kar SS, Palui R, Roy A*
- 57 Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis  
*Lopes MB, Lyra AC, Rocha R, Coqueiro FG, Lima CA, de Oliveira CC, Santana GO*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastrointestinal Pharmacology and Therapeutics*, Juan Lucas Poggio, MD, MS, Professor, Department of Surgery, Temple University Hospital, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19101, United States. [juan.poggio@tuhs.temple.edu](mailto:juan.poggio@tuhs.temple.edu)

**AIMS AND SCOPE**

The primary aim of the *World Journal of Gastrointestinal Pharmacology and Therapeutics* (WJGPT, *World J Gastrointest Pharmacol Ther*) is to provide scholars and readers from various fields of gastrointestinal pharmacology and therapeutics with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGPT mainly publishes articles reporting research results obtained in the field of gastrointestinal pharmacology and therapeutics and covering a wide range of topics including acid-related disorders, functional gastrointestinal disorders, fundamentals of gastrointestinal pharmacology, etc.

**INDEXING/ABSTRACTING**

The WJGPT is now abstracted and indexed in PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Li Wang.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Pharmacology and Therapeutics*

**ISSN**

ISSN 2150-5349 (online)

**LAUNCH DATE**

May 6, 2010

**FREQUENCY**

Bimonthly

**EDITORS-IN-CHIEF**

Emanuele Sinagra

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2150-5349/editorialboard.htm>

**PUBLICATION DATE**

July 5, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/gerinfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/gerinfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/gerinfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Observational Study

# Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis

Mirella Brasil Lopes, Andre Castro Lyra, Raquel Rocha, Fernanda Gomes Coqueiro, Carla Andrade Lima, Carolina Cunha de Oliveira, Genoile Oliveira Santana

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:**

Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): 0  
Grade C (Good): C, C  
Grade D (Fair): D, D  
Grade E (Poor): 0

**P-Reviewer:** Lakatos PL, Canada; Mahmoudi E, Iran; Jin X, China

**A-Editor:** Nakaji K, Japan

**Received:** January 28, 2022

**Peer-review started:** January 28, 2022

**First decision:** March 10, 2022

**Revised:** April 27, 2022

**Accepted:** May 28, 2022

**Article in press:** May 28, 2022

**Published online:** July 5, 2022



**Mirella Brasil Lopes, Andre Castro Lyra, Carla Andrade Lima, Genoile Oliveira Santana,** Programa de Pós-graduação em Medicina e Saúde, Universidade Federal da Bahia, Salvador 40110-060, Brazil

**Raquel Rocha, Fernanda Gomes Coqueiro,** Departamento Ciências da Nutrição, Universidade Federal da Bahia, Salvador 40110-060, Brazil

**Carolina Cunha de Oliveira,** Departamento de Nutrição, Universidade Federal de Sergipe, Lagarto 49060-110, Brazil

**Genoile Oliveira Santana,** Departamento Ciências da Vida, Universidade do Estado da Bahia, Salvador 41.150-000, Brazil

**Corresponding author:** Raquel Rocha, DSc, MSc, Academic Research, Adjunct Associate Professor, Ciências da Nutrição, Universidade Federal da Bahia, Avenida Araújo Pinho, 32, Salvador 40110-060, Brazil. [raquelrocha2@yahoo.com.br](mailto:raquelrocha2@yahoo.com.br)

## Abstract

### BACKGROUND

Low bone mineral density (BMD) is common in patients with inflammatory bowel disease. However, nutritional risk factors for low BMD in the ulcerative colitis (UC) population are still poorly understood.

### AIM

To investigate the association of anthropometric indicators and body composition with BMD in patients with UC.

### METHODS

This is a cross-sectional study on adult UC patients of both genders who were followed on an outpatient basis. A control group consisting of healthy volunteers, family members, and close people was also included. The nutritional indicators evaluated were body mass index (BMI), total body mass (TBM), waist circumference (WC), body fat in kg (BFkg), body fat in percentage (BF%), trunk BF (TBF), and also lean mass. Body composition and BMD assessments were performed by dual-energy X-ray absorptiometry.

### RESULTS

The sociodemographic characteristics of patients with UC ( $n = 68$ ) were similar to those of healthy volunteers ( $n = 66$ ) ( $P > 0.05$ ). Most patients (97.0%) were in remission of the disease, 58.8% were eutrophic, 33.8% were overweight, 39.0% had high WC, and 67.6% had excess BF%. However, mean BMI, WC, BFkg, and TBF of UC patients were lower when compared to those of the control group ( $P < 0.05$ ). Reduced BMD was present in 41.2% of patients with UC (38.2% with osteopenia and 2.9% with osteoporosis) and 3.0% in the control group ( $P < 0.001$ ). UC patients with low BMD had lower BMI, TBM, and BFkg values than those with normal BMD ( $P < 0.05$ ). Male patients were more likely to have low BMD (prevalence ratio [PR] = 1.86; 95% confidence interval [CI]: 1.07-3.26). Those with excess weight (PR = 0.43; 95%CI: 0.19-0.97) and high WC (PR = 0.44; 95%CI: 0.21-0.94) were less likely to have low BMD.

## CONCLUSION

Patients with UC in remission have a high prevalence of metabolic bone diseases. Body fat appears to protect against the development of low BMD in these patients.

**Key Words:** Ulcerative colitis; Bone mineral density; Body composition; Fat body; Abdominal fat

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** There is a high prevalence of osteopenia/osteoporosis in adult outpatients with ulcerative colitis in remission. Patients with ulcerative colitis had a 22.4 times greater chance of developing reduced bone mineral density than healthy individuals. Lower values of body mass index and body fat indicators were identified in patients with ulcerative colitis with low bone mineral density. Low bone mineral density was associated with males and those without excess weight and with normal waist circumference.

**Citation:** Lopes MB, Lyra AC, Rocha R, Coqueiro FG, Lima CA, de Oliveira CC, Santana GO. Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis. *World J Gastrointest Pharmacol Ther* 2022; 13(4): 57-66

**URL:** <https://www.wjgnet.com/2150-5349/full/v13/i4/57.htm>

**DOI:** <https://dx.doi.org/10.4292/wjgpt.v13.i4.57>

## INTRODUCTION

Low bone mineral density (BMD) is often seen in patients with inflammatory bowel disease (IBD)[1,2]. Patients with Crohn's disease and ulcerative colitis (UC), the main types of IBD, are at increased risk of fracture compared to healthy controls, with an osteoporotic fracture risk around 32%[3-6]. In patients with UC, the prevalence of osteoporosis varies between 2% to 9%[7].

The cause of osteoporosis in patients with IBD is multifactorial. Most studies involving patients with UC demonstrate that the main risk factors for this disease are related to genetics, chronic inflammatory status, treatment with steroids, and low weight[8-10].

Nutritional status appears to influence the BMD of patients with IBD. The inflammatory process and complications of the disease in the active phase can lead to compromised nutritional status, with reduced body mass and muscle mass reserves and micronutrient deficiency, and consequently to low BMD and increased risk of osteoporotic fractures[11,12]. Although the increased prevalence of overweight/obesity is evident in patients with UC, studies explaining the relationship between abdominal fat and disease complications in this group of patients are limited[13].

Studies that demonstrate the relationship between nutritional risk factors and low BMD are more frequent among patients with CD considering the extension and severity of the disease, which can compromise the main sites of nutrient absorption. Thus, there is little evidence that brings the relationship of nutritional risk factors with the development of reduced BMD in patients with UC. The aim of the present study was to investigate the association of indicators of total body mass and body composition with BMD in patients with UC.

## MATERIALS AND METHODS

### Study design and patients

This is a cross-sectional study involving adult outpatients with UC from two reference centers. Consecutive patients with a diagnosis of UC confirmed by clinical, endoscopic, radiological, and

histological criteria were included[14]. The control group consisted of healthy volunteers, family members, and close people with the same sociodemographic characteristics and lifestyle compared to the UC group. Volunteers recruited were matched for gender and age, with no history of bowel surgery or taking medications known to affect bone turnover.

Elderly people, pregnant women, patients with diseases that cause changes in bone metabolism (chronic renal failure, chronic obstructive pulmonary disease, thyroid disease, liver disease, and systemic lupus erythematosus), malignant diseases, diabetes mellitus, or celiac disease, menopausal or post-menopausal patients, and those in use of estrogen therapy were not included in the study.

### **Clinical data**

The clinical criteria for patients with UC were activity index and disease duration, past history of intestinal resection, accumulated dose of glucocorticoids in the last year, use of glucocorticoids for 3 mo or more, extent of disease according to Montreal classification[15], and serum calcium, albumin, and C-reactive protein (CRP) levels, in addition to smoking, regular physical activity[16], and use of calcium and vitamin D supplements.

Disease activity was assessed by the Lichtiger index[17], considering activity when a score  $\geq 10$  points. Calcium (mmol/L) and serum albumin (g/dL) and CRP (mg/L) were collected on the same day as the BMD evaluation and performed in the same laboratory. Calcium and albumin were measured using the dry chemical method and CRP was measured by the turbidimetry method.

### **Anthropometric assessment and body composition**

Anthropometric measurements were performed by a trained and standardized team. Height (in centimeters) and body weight (in kg) were measured in duplicate, with subjects wearing light clothing and without shoes, using a scale (Filizola, São Paulo, Brazil), 150 kg capacity and 100 g interval, with an attached stadiometer with a 0.5 cm scale. The body mass index (BMI) was obtained using the formula weight/height<sup>2</sup> and classified according to the World Health Organization[18]. For statistical analysis, two groups were considered, those with excess weight (BMI  $\geq 25.0$  kg/m<sup>2</sup>) and those without (BMI  $< 25.0$  kg/m<sup>2</sup>).

Waist circumference (WC) was measured with the individual in an upright position, with feet together and without shoes. The measurement was taken with an inelastic measuring tape, which circled the individual at the midpoint between the iliac crest and the last rib[18]. High WC was considered when  $\geq 80$  cm for women and  $\geq 90$  cm for men[19].

The evaluation of body composition was performed by dual-energy X-ray absorptiometry (DXA) of the total body using a Prodigy Lunar Bone Densitometer (GE Medical Systems, United States). The equipment calibration followed the manufacturer's recommendations and both the calibration and analysis were performed by a single technician with experience in this type of assessment. The values of total body fat in percentage (BF%), total body fat in kilograms (BFkg), trunk body fat in kg (TBF), and lean mass in kilograms (LBM) were obtained. The percentage of body fat (BF%) was considered high when  $\geq 25\%$  for men and  $\geq 32\%$  for women[18].

### **Bone mineral density assessment**

BMD was determined by DXA in the whole body, lumbar spine (L1-L4), and femoral neck. Results of DMO are expressed in g/cm<sup>2</sup> and also presented as T-score or Z-score. The BMD classification was based on the T-score for men 50 years of age and older and patients with UC and the Z-score for those younger than 50 years of age for men and premenopausal women. For patients with UC, the T-score was used regardless of age, considering the possibility of secondary loss of bone mass determined by the underlying disease or by the therapies used. According to the T-score, the BMD was normal up to 1 standard deviation (SD), with osteopenia values below -1 and above -2.5 SD and with osteoporosis  $\leq -2.5$  SD. For the Z-score, BMD  $\leq -2.0$  SD was considered below the estimated for the age group (BMD reduced for age). In the osteopenia/osteoporosis classification, the bone sites of the femoral neck or lumbar spine were used[20].

### **Statistical analysis**

Results are expressed as proportions for categorical variables, the mean and SD for continuous variables with a normal distribution, and median and interquartile range for variables without a normal distribution. Mann-Whitney test was used to compare continuous variables and the chi-square test or Fisher's exact test to compare categorical variables. Poisson regression analysis with robust variance was used to obtain estimates of the prevalence ratio and the respective 95% confidence interval (CI). For all tests, a *P*-value  $< 0.05$  was considered statistically significant. The Statistical Package for Social Science program (SPSS, Chicago, IL, United States, version 21.0) was used for data tabulation and analysis.

### **Ethical considerations**

Informed consent was obtained from all participants and the Ethics Committee of the University Hospital Professor Edgar Santos approved the study protocol (n°117/2011).

**Table 1** Demographic, clinical, nutritional, and bone density characteristics of patients with ulcerative colitis


| Variable                                             | UC (n = 68)      | Control (n = 66) | P value |
|------------------------------------------------------|------------------|------------------|---------|
| Age (yr), median (IR)                                | 39.0 (31.0-44.8) | 36.5 (29.0-43.0) | 0.484   |
| Sex (female), n (%)                                  | 42 (61.8)        | 39 (59.1)        | 0.867   |
| Smoking (yes), n (%)                                 | 2 (2.9)          | 4 (6.1)          | 0.437   |
| Regular physical activity (yes), n (%)               | 16 (23.5)        | 15 (22.7)        | 1.000   |
| Duration of illness (yes), median (IR)               | 5.0 (2.0-8.0)    |                  |         |
| Disease remission (yes), n (%)                       | 66 (97.1)        |                  |         |
| Intestinal resection history (yes), n (%)            | 2 (2.9)          |                  |         |
| Extent of disease, n (%)                             |                  |                  |         |
| Proctitis                                            | 13 (19.1)        |                  |         |
| Left colitis                                         | 25 (36.8)        |                  |         |
| Extensive colitis                                    | 30 (44.1)        |                  |         |
| Use of glucocorticoids (yes), n (%)                  | 12 (17.6)        |                  |         |
| Use ≥ 3 mo (yes), n (%)                              | 8 (66.7)         |                  |         |
| Accumulated dose of glucocorticoids (g), median (IR) | 1.7 (1.2-2.5)    |                  |         |
| Calcium supplement (yes), n (%)                      | 3 (4.4)          | 0 (0)            | 0.245   |
| Vit D supplement (yes), n (%)                        | 5 (7.4)          | 0 (0)            | 0.058   |
| Serum calcium (mmol/L), median (IR)                  | 2.3 (2.2-2.4)    | 2.4 (2.3-2.4)    | 0.065   |
| Serum albumin (g/dL), median (IR)                    | 4.3 (4.1-4.5)    | 4.4 (4.1-4.6)    | 0.801   |
| C-RP mg/dL, median (IR)                              | 1.4 (0.6-5.2)    | 5.0 (1.0-6.2)    | 0.004   |
| BMI (kg/m <sup>2</sup> ), median (IR)                | 23.7 (20.6-26.5) | 26.3 (22.8-29.0) | 0.16    |
| BMI classification, n (%)                            |                  |                  | 0.020   |
| Thinness                                             | 5 (7.4)          | 1 (1.5)          |         |
| Eutrophy                                             | 40 (58.8)        | 26 (39.4)        |         |
| Overweight                                           | 16 (23.5)        | 28 (42.4)        |         |
| Obesity                                              | 7 (10.3)         | 11 (16.7)        |         |
| WC (cm), median (IR)                                 | 80.5 (72.0-89.1) | 84.6 (79.7-93.7) | 0.156   |
| LBM (kg), median (IR)                                | 40.1 (34.5-49.4) | 41.5 (35.3-52.2) | 0.604   |
| BF (kg), median (IR)                                 | 17.8 (11.5-22.6) | 23.2 (17.8-28.4) | 0.001   |
| BF (%), median (IR)                                  | 32.9 (23.7-37.6) | 34.8 (28.1-42.3) | 0.168   |
| TBF (kg), median (IR)                                | 8.6 (6.3-12.5)   | 12.8 (7.8-16.5)  | 0.354   |
| BMD (g/cm <sup>2</sup> ), median (IR)                |                  |                  |         |
| Femoral neck                                         | 0.99 (0.90-1.07) | 1.06 (0.96-1.15) | 0.120   |
| Lumbar spine                                         | 1.16 (1.08-1.26) | 1.21 (1.13-1.31) | 0.120   |
| Total body                                           | 1.17 (1.11-1.24) | 1.22 (1.19-1.29) | 0.000   |

UC: Ulcerative colitis; SD: Standard deviation; IR: Interquartile range; BMI: Body mass index; WC: Waist circumference; LBM: Lean body mass; BF: Body fat; TBF: Trunk body fat; BMD: Bone density; C-RP: C-reactive protein.

## RESULTS

### *Clinical and nutritional characteristics*

In this study, 68 patients with UC and 66 people in the control group were included. In both groups, the majority were female and demographics, lifestyle, and use of nutritional supplements were similar ( $P > 0.05$ ) (Table 1).



**Figure 1 Anthropometry and body composition according to bone mineral density in patients with ulcerative colitis.** <sup>a</sup> $P < 0.05$  (Mann-Whitney test). BMI: Body mass index; TBM: Total body mass; WC: Waist circumference; BF: Body fat; TBF: Trunk body fat; LBM: Lean body mass.

Most patients (97.0%) were in remission of the disease, only 2.9% had a previous history of intestinal resection, and extensive colitis was present in 44.1%. The use of steroids in the last year occurred in 17.6% of the patients, and of these, 66.7% used it for 3 mo or more (Table 1).

Regarding the anthropometric nutritional status, it was observed that the majority of UC patients had normal weight (58.8%); however, the frequency of overweight was high (33.8%), with six (8.8%) having grade I obesity and one (1.5%) having grade II. Women had higher BF% (37.3% *vs* 19.7%;  $P = 0.00$ ), BFkg (22.5kg *vs* 12.7 kg;  $P = 0.00$ ), and TBF (10.8kg *vs* 7.3 kg;  $P = 0.00$ ) than men. BFkg and TBF of UC patients were statistically lower compared to those of the control group ( $P < 0.05$ ) (Table 1).

### BMD characteristics

Low BMD was present in 41.2% ( $n = 28$ ) of patients with UC (38.2% with osteopenia and 2.9% with osteoporosis) and in 3.0% ( $n = 2$ ) in the control group ( $P < 0.001$ ). It was observed that UC patients had a 22.4 times greater chance of developing reduced BMD than healthy individuals (odds ratio = 22.4; 95%CI: 5.06 – 99.19). The majority (71.4%; 20/28) of UC patients with low BMD were younger than 45 years of age. The BMD of total body in UC patients was statistically lower compared to that of the control group ( $P < 0.05$ ) (Table 1).

UC patients who had low BMD were mostly male, without regular physical activity, and had left colitis compared to those with normal BMD ( $P < 0.05$ ) (Table 2). Serum calcium had a lower concentration in those with low BMD, although with a clinically irrelevant difference (Table 2). Low BMD occurred equally at both sites, the spine and femur.

Individuals in the control group who had low BMD (3.0%; 2/66) had osteopenia located in the lumbar spine, and all were female and without regular physical activity.

### Anthropometric indicators and body composition vs BMD

Male patients with UC were more likely to have low BMD (PR = 1.86; 95%CI: 1.07-3.26), and those with excess weight (prevalence ratio [PR] = 0.29; 95%CI: 0.13-0.66) and high WC (PR = 0.36; 95%CI = 0.17-0.75) were less likely to have low BMD (Table 3). Patients with UC with low BMD had a lower BMI value than those with normal BMD (22.8 [20.5-24.4] *vs* 25.6 [21.9-28.4] kg/m<sup>2</sup>;  $P = 0.02$ ), TBM (58.5 [52.7-65.7] *vs* 67.4 [59.1-76.8] kg;  $P = 0.02$ ), and BFkg (17.2 [9.9-21.3] *vs* 21.2 [15.4-28.4] kg;  $P = 0.01$ ) (Figure 1).

No significant differences were found in anthropometric nutritional characteristics or body composition between those with UC with low and normal BMD when stratified by sex.

## DISCUSSION

Our data demonstrate that in a sample of patients with UC, predominantly in remission, with reduced frequency of glucocorticoid use and excess body fat, low BMD had a high prevalence, in patients under 45 years of age, being that excess weight and abdominal fat are associated with normal BMD.

**Table 2 Demographic and clinical characteristics according to normal and low bone mineral density of patients with ulcerative colitis**

| Variable                                             | Normal BMD (n = 40) | Low BMD (n = 28) | P value |
|------------------------------------------------------|---------------------|------------------|---------|
| Age (yr), median (IR)                                | 37.5 (30.0-43.0)    | 40.0 (32.5-46.0) | 0.193   |
| Age group, n (%)                                     |                     |                  |         |
| < 45 yr                                              | 31 (77.5)           | 20 (71.4)        | 0.57    |
| ≥ 45 yr                                              | 9 (22.5)            | 8 (28.6)         |         |
| Sex, n (%)                                           |                     |                  |         |
| Male                                                 | 11 (27.5)           | 15 (53.6)        | 0.03    |
| Female                                               | 29 (72.5)           | 13 (46.4)        |         |
| Regular physical activity, n (%)                     |                     |                  |         |
| No                                                   | 27 (67.5)           | 25 (89.3)        | 0.04    |
| Yes                                                  | 13 (32.5)           | 3 (10.7)         |         |
| Duration of illness (yr), median (IR)                | 5.0 (2.0-9.0)       | 4.5 (1.2-6.7)    | 0.98    |
| Extent of disease, n (%)                             |                     |                  |         |
| Proctitis                                            | 12 (30.0)           | 1 (3.6)          | 0.01    |
| Left colitis                                         | 11 (27.5)           | 14 (50.0)        |         |
| Extensive colitis                                    | 17 (42.5)           | 13 (46.4)        |         |
| Use of glucocorticoids, n (%)                        |                     |                  |         |
| No                                                   | 33 (84.6)           | 22 (78.6)        | 0.75    |
| Yes                                                  | 6 (15.4)            | 6 (21.4)         |         |
| Use of glucocorticoids ≥ 3 mo, n (%)                 |                     |                  |         |
| No                                                   | 3 (50.0)            | 1 (16.7)         | 0.54    |
| Yes                                                  | 3 (50.0)            | 5 (83.3)         |         |
| Accumulated dose of glucocorticoids (g), median (IR) | 1.8 (1.3-2.3)       | 1.5 (1.1-3.5)    | 0.55    |
| Serum calcium (mmol/L), median (IR)                  | 2.3 (2.3-2.4)       | 2.2 (2.2-2.3)    | 0.03    |
| Serum albumin (g/dL), median (IR)                    | 4.4 (4.1-4.6)       | 4.3 (4.0-4.5)    | 0.57    |
| PCR mg/dL, median (IR)                               | 3.1 (0.9-6.1)       | 1.6 (1.6-6.3)    | 0.56    |

SD: Standard deviation; IR: Interquartile range; BMD: Bone mineral density; C-RP: C-reactive protein.

It is recommended that patients with IBD be screened based on established guidelines for the general population (pre-existing fragility fracture, women aged 65 years and older and men aged 70 years and older, and those with risk factors that increase probability of detecting low bone mass)[21]. However, this is a matter of concern considering that in this sample the majority of patients with UC with reduced BMD were younger than 45 years of age, with reduced frequency of glucocorticoid use and in remission.

Bone mass loss is a frequent complication in patients with UC[22-24] and with a higher prevalence when compared to that in healthy controls[25]. Greater bone fragility increases the risk of fractures, and consequently morbidity and reduced quality of life for patients. The mechanisms reported in the literature associated with bone loss in UC patients are mainly related to the UC itself, the use of steroids, hospitalization[25-27], and low BMI values[28-31].

The role of obesity in patients with IBD is still uncertain, although initially it is believed that the greater inflammatory potential of adipose tissue could have a negative impact on the evolution of the disease in these patients[32,33]. The effect of body weight on bone mass can be attributed to the mechanical compression of weight on the skeleton, and in response, it increases bone mass to accommodate greater load[34]. In UC patients, obesity appears to be associated with a lower risk of low BMD[35], with a 5 kg/m<sup>2</sup> increase in BMI decreasing by 57% the chance of having low BMD in 327 patients with UC and ileo-anal anastomosis with pouch illegitimate[29].

The effects of body fat on BMD in patients with IBD have been discussed[36], considering the increase in the prevalence of overweight individuals diagnosed with UC[37,38]. Although there is no clear consensus in the literature, body fat seems to have a positive effect on bone mass, as a result of the anabolic effect of mechanical tension of the fat mass on bone, in addition to the action of hormones

**Table 3 Prevalence and prevalence ratio of low bone mineral density according to demographic, clinical, and nutritional characteristics of patients with ulcerative colitis**

| Variable                  | Prevalence of low BMD, n (%) |      | PR (95%CI)         | P value |
|---------------------------|------------------------------|------|--------------------|---------|
| Sex                       |                              |      |                    |         |
| Female                    | 15                           | 57.7 | 1.00               |         |
| Male                      | 13                           | 31.0 | 1.86 (1.07 – 3.26) | 0.029   |
| Age group                 |                              |      |                    |         |
| < 45 yr                   | 20                           | 39.2 | 1.00               |         |
| ≥ 45 yr                   | 8                            | 47.1 | 1.38 (0.46 – 4.16) | 0.583   |
| Regular physical activity |                              |      |                    |         |
| Yes                       | 3                            | 18.8 | 1.00               |         |
| No                        | 25                           | 48.1 | 2.56 (0.89 – 7.39) | 0.081   |
| Steroid use               |                              |      |                    |         |
| No                        | 23                           | 38.3 | 1.00               |         |
| Yes                       | 5                            | 62.5 | 1.63 (0.87 – 3.05) | 0.126   |
| Steroid use               |                              |      |                    |         |
| < 3 mo                    | 1                            | 25.0 | 1.00               |         |
| ≥ 3 mo                    | 5                            | 62.5 | 2.50 (0.42 – 14.8) | 0.313   |
| BMI classification        |                              |      |                    |         |
| Not overweight            | 23                           | 51.1 | 1.00               |         |
| Overweight                | 5                            | 21.7 | 0.43 (0.19 – 0.97) | 0.043   |
| WC classification         |                              |      |                    |         |
| Normal                    | 21                           | 52.5 | 1.00               |         |
| Elevated                  | 6                            | 23.1 | 0.44 (0.21 – 0.94) | 0.034   |
| BF classification (%)     |                              |      |                    |         |
| Normal                    | 10                           | 45.5 | 1.00               |         |
| Elevated                  | 18                           | 39.1 | 0.86 (0.48 – 1.54) | 0.614   |

PR: Prevalence ratio; CI: Confidence interval; BMI: Body mass index; WC: Waist circumference; BF: Body fat; BMD: Bone density; C-RP: C-reactive protein.

released by adipocytes, which influence the activities of bone cells, both osteoblasts and osteoclasts[34].

The influence of gender on the BMD of patients with IBD is discordant[1,4]. In our study, male patients were more likely to have reduced BMD, which we suppose at the expense of lower body fat compared to females.

No studies were found evaluating the association between WC/abdominal fat and BMD in patients with IBD. It is known that the relationship between abdominal fat and BMD is quite complex and the results of studies in the general population are conflicting[39,40]. The two adipose tissues present in the abdominal region (subcutaneous and visceral) are highly metabolic, with the production of adipokines, estrogens, and metabolic factors derived from bones, with feedback mechanisms that affect bone remodeling and body composition[40].

Our study has some limitations. For example, serum levels of alkaline phosphatase, parathyroid hormone, and vitamin D were not measured in this study. On the other hand, it has the advantage of assessing body mass by DXA. More robust, prospective studies with larger samples and techniques for more accurate quantification of adipose tissues are needed to better explain the relationship between total and abdominal body fat and BMD.

## CONCLUSION

In conclusion, we observed that male UC patients in remission have a high prevalence of metabolic bone diseases, and nutritional parameters related to body fat seem to protect against the development of low

BMD. Understanding the protective effect that each nutritional component exerts on the bone mass of patients with IBD is important to assist in the development of strategies that can provide the control of metabolic bone diseases in these patients.

## ARTICLE HIGHLIGHTS

### Research background

Inflammatory bowel disease is associated with complications such as low bone mineral density and increased risk of fracture compared to healthy controls. In patients with ulcerative colitis, the prevalence of osteoporosis varies between 2% to 9% and the main risk factors are related to genetics, chronic inflammatory status, treatment with steroids, and low weight.

### Research motivation

There is little evidence that brings the relationship of nutritional risk factors with the development of reduced bone mineral density (BMD) in patients with ulcerative colitis, despite the studies demonstrating the relationship between nutritional risk factors and low BMD are more frequent in patients with Crohn's disease, considering the extension and severity of factors the disease, which can compromise the main sites of nutrient absorption

### Research objectives

To investigate the association of indicators of total body mass and body composition with BMD in patients with ulcerative colitis (UC).

### Research methods

This is a cross-sectional study on adult UC patients of both genders who were followed on an outpatient basis. A control group consisting of healthy volunteers, family members, and close people was also included. The nutritional indicators evaluated were body mass index (BMI), total body mass (TBM), waist circumference (WC), body fat in kg (BFkg), BF in percentage (BF%), trunk body fat (TBF), and also lean mass. Body composition and BMD assessments were performed by dual-energy X-ray absorptiometry.

### Research results

Most UC patients (97.0%) were in remission of the disease, 58.8% were eutrophic, 33.8% were overweight, 39.0% had high WC, and 67.6% had excess BF%. However, mean BMI, WC, BFkg, and TBF of UC patients were lower when compared to those of the control group ( $P < 0.05$ ). Reduced BMD was present in 41.2% of patients with UC (38.2% with osteopenia and 2.9% with osteoporosis) and 3.0% in the control group ( $P < 0.001$ ). UC patients with low BMD had lower BMI, TBM, and BFkg values than those with normal BMD ( $P < 0.05$ ). Male patients were more likely to have low BMD (prevalence ratio [PR] = 1.86; 95% confidence interval [CI]: 1.07–3.26). Those with excess weight (PR = 0.43; 95% CI: 0.19–0.97) and high WC (PR = 0.44; 95% CI = 0.21–0.94) were less likely to have low BMD.

### Research conclusions

Patients with UC in remission have a high prevalence of metabolic bone diseases and body fat appears to protect against the development of low BMD in these patients

### Research perspectives

The future perspective is to evaluate other nutritional characteristics such as food consumption.

## FOOTNOTES

**Author contributions:** Lopes MB, Rocha R, Coqueiro FG, and Santana GO designed the research; Lopes MB, Coqueiro FG, and Lima CA performed the research; Lopes MB, Rocha R, and de Oliveira CC analyzed the data; Lopes MB, Lyra AC, Rocha R, and Santana GO wrote the paper.

**Institutional review board statement:** The Ethics Committee of the University Hospital Professor Edgar Santos approved the study protocol (n°117/2011).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All authors declare that they have no conflict of interest to disclose.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at [raquelrocha2@yahoo.com.br](mailto:raquelrocha2@yahoo.com.br). Participants gave informed consent for data sharing. No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Brazil

**ORCID number:** Mirella Brasil Lopes 0000-0003-1393-8391; Andre Castro Lyra 0000-0001-9010-8645; Raquel Rocha 0000-0002-2687-2080; Fernanda Gomes Coqueiro 0000-0003-4405-218X; Carla Andrade Lima 0000-0002-3123-4665; Carolina Cunha de Oliveira 0000-0003-1196-0683; Genoile Oliveira Santana 0000-0001-5936-9791.

**S-Editor:** Wang LL

**L-Editor:** Wang TQ

**P-Editor:** Wang LL

## REFERENCES

- 1 **Even Dar R**, Mazor Y, Karban A, Ish-Shalom S, Segal E. Risk Factors for Low Bone Density in Inflammatory Bowel Disease: Use of Glucocorticoids, Low Body Mass Index, and Smoking. *Dig Dis* 2019; **37**: 284-290 [PMID: [30799399](#) DOI: [10.1159/000496935](#)]
- 2 **Casals-Seoane F**, Chaparro M, Maté J, Gisbert JP. Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study. *Inflamm Bowel Dis* 2016; **22**: 1929-1936 [PMID: [27135482](#) DOI: [10.1097/mib.0000000000000815](#)]
- 3 **Tsai MS**, Lin CL, Tu YK, Lee PH, Kao CH. Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. *Int J Clin Pract* 2015; **69**: 235-241 [PMID: [25472555](#) DOI: [10.1111/ijcp.12526](#)]
- 4 **Bartko J**, Reichardt B, Kocijan R, Klaushofer K, Zwerina J, Behanova M. Inflammatory Bowel Disease: A Nationwide Study of Hip Fracture and Mortality Risk After Hip Fracture. *J Crohns Colitis* 2020; **14**: 1256-1263 [PMID: [32170313](#) DOI: [10.1093/ecco-jcc/ijaa052](#)]
- 5 **Szafors P**, Che H, Barnette T, Morel J, Gaujoux-Viala C, Combe B, Lukas C. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. *Osteoporos Int* 2018; **29**: 2389-2397 [PMID: [29909470](#) DOI: [10.1007/s00198-018-4586-6](#)]
- 6 **Hidalgo DF**, Boonpheng B, Phemister J, Hidalgo J, Young M. Inflammatory Bowel Disease and Risk of Osteoporotic Fractures: A Meta-Analysis. *Cureus* 2019; **11**: e5810 [PMID: [31720198](#) DOI: [10.7759/cureus.5810](#)]
- 7 **Kärnsund S**, Lo B, Bendtsen F, Holm J, Burisch J. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. *World J Gastroenterol* 2020; **26**: 5362-5374 [PMID: [32994694](#) DOI: [10.3748/wjg.v26.i35.5362](#)]
- 8 **Khan ZAW**, Shetty S, Pai GC, Acharya KKV, Nagaraja R. Prevalence of low bone mineral density in inflammatory bowel disease and factors associated with it. *Indian J Gastroenterol* 2020; **39**: 346-353 [PMID: [32940845](#) DOI: [10.1007/s12664-020-01048-5](#)]
- 9 **Komaki Y**, Komaki F, Micic D, Ido A, Sakuraba A. Risk of Fractures in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2019; **53**: 441-448 [PMID: [29672437](#) DOI: [10.1097/mcg.0000000000001031](#)]
- 10 **Sgambato D**, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E, Miranda A, De Mauro D, Romano L, Iolascon G, Romano M. Bone alterations in inflammatory bowel diseases. *World J Clin Cases* 2019; **7**: 1908-1925 [PMID: [31423424](#) DOI: [10.12998/wjcc.v7.i15.1908](#)]
- 11 **Targownik LE**, Bernstein CN, Leslie WD. Risk factors and management of osteoporosis in inflammatory bowel disease. *Curr Opin Gastroenterol* 2014; **30**: 168-174 [PMID: [24419292](#) DOI: [10.1097/mog.0000000000000037](#)]
- 12 **Ratajczak AE**, Szymczak-Tomeczak A, Skrzypczak-Zielińska M, Rychter AM, Zawada A, Dobrowolska A, Krela-Kazmierczak I. Vitamin C Deficiency and the Risk of Osteoporosis in Patients with an Inflammatory Bowel Disease. *Nutrients* 2020; **12** [PMID: [32751086](#) DOI: [10.3390/nu12082263](#)]
- 13 **Karaskova E**, Velganova-Veghova M, Geryk M, Foltenova H, Kucerova V, Karasek D. Role of Adipose Tissue in Inflammatory Bowel Disease. *Int J Mol Sci* 2021; **22** [PMID: [33921758](#) DOI: [10.3390/ijms22084226](#)]
- 14 **Dignass A**, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 2012; **6**: 991-1030 [PMID: [23040451](#) DOI: [10.1016/j.crohns.2012.09.002](#)]
- 15 **Silverberg MS**, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K,

- Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; **19** Suppl A: 5A-36A [PMID: [16151544](#) DOI: [10.1155/2005/269076](#)]
- 16 **Global Recommendations on Physical Activity for Health.** Geneva: World Health Organization; 2010 [PMID: [26180873](#)]
- 17 **Lichtiger S**, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med* 1994; **330**: 1841-1845 [PMID: [8196726](#) DOI: [10.1056/nejm199406303302601](#)]
- 18 **Physical status: the use and interpretation of anthropometry.** Report of a WHO Expert Committee. *World Health Organ Tech Rep Ser* 1995; **854**: 1-452 [PMID: [8594834](#) DOI: [10.1017/s0021932098261359](#)]
- 19 **Alberti KG**, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006; **23**: 469-480 [PMID: [16681555](#) DOI: [10.1111/j.1464-5491.2006.01858.x](#)]
- 20 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1994; **843**: 1-129 [PMID: [7941614](#) DOI: [10.5144/0256-4947.1994.527](#)]
- 21 **Farraye FA**, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. *Am J Gastroenterol* 2017; **112**: 241-258 [PMID: [28071656](#) DOI: [10.1038/ajg.2016.537](#)]
- 22 **Ediz L**, Dülger AC, Toprak M, Ceylan MF, Kemik O. The prevalence and risk factors of decreased bone mineral density in firstly diagnosed ulcerative colitis patients in the eastern region of Turkey. *Int J Clin Exp Med* 2011; **4**: 157-163 [PMID: [21686139](#) DOI: [10.1177/147323001103900307](#)]
- 23 **Ismail MH**, Al-Elq AH, Al-Jarodi ME, Azzam NA, Aljebreen AM, Al-Momen SA, Bseiso BF, Al-Mulhim FA, Alquorain A. Frequency of low bone mineral density in Saudi patients with inflammatory bowel disease. *Saudi J Gastroenterol* 2012; **18**: 201-207 [PMID: [22626800](#) DOI: [10.4103/1319-3767.96458](#)]
- 24 **Ewid M**, Al Mutiri N, Al Omar K, Shamsan AN, Rathore AA, Saquib N, Salaas A, Al Sarraj O, Nasri Y, Attal A, Tawfiq A, Sherif H. Updated bone mineral density status in Saudi patients with inflammatory bowel disease. *World J Gastroenterol* 2020; **26**: 5343-5353 [PMID: [32994692](#) DOI: [10.3748/wjg.v26.i35.5343](#)]
- 25 **Lima CA**, Lyra AC, Rocha R, Santana GO. Risk factors for osteoporosis in inflammatory bowel disease patients. *World J Gastrointest Pathophysiol* 2015; **6**: 210-218 [PMID: [26600979](#) DOI: [10.4291/wjgp.v6.i4.210](#)]
- 26 **Wu F**, Huang Y, Hu J, Shao Z. Mendelian randomization study of inflammatory bowel disease and bone mineral density. *BMC Med* 2020; **18**: 312 [PMID: [33167994](#) DOI: [10.1186/s12916-020-01778-5](#)]
- 27 **Zhou T**, Pan J, Lai B, Cen L, Jiang W, Yu C, Shen Z. Bone mineral density is negatively correlated with ulcerative colitis: a systematic review and meta-analysis. *Clin Transl Med* 2020; **9**: 18 [PMID: [32072320](#) DOI: [10.1186/s40169-020-00270-0](#)]
- 28 **Dinca M**, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, Naccarato R, Martin A. Evolution of osteopenia in inflammatory bowel disease. *Am J Gastroenterol* 1999; **94**: 1292-1297 [PMID: [10235209](#) DOI: [10.1111/j.1572-0241.1999.01079.x](#)]
- 29 **Shen B**, Remzi FH, Oikonomou IK, Lu H, Lashner BA, Hammel JP, Skugor M, Bennett AE, Brzezinski A, Queener E, Fazio VW. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. *Am J Gastroenterol* 2009; **104**: 639-646 [PMID: [19262520](#) DOI: [10.1038/ajg.2008.78](#)]
- 30 **Poturoglu S**, Balkan F, Karaali ZE, Ibrisim D, Yanmaz S, Aktuglu MB, Alioglu T, Kendir M. Relationship between bone mineral density and clinical features in patients with inflammatory bowel disease: a local study in Turkish population. *J Int Med Res* 2010; **38**: 62-68 [PMID: [20233514](#) DOI: [10.1177/147323001003800107](#)]
- 31 **Wada Y**, Hisamatsu T, Naganuma M, Matsuoka K, Okamoto S, Inoue N, Yajima T, Kouyama K, Iwao Y, Ogata H, Hibi T, Abe T, Kanai T. Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study. *Clin Nutr* 2015; **34**: 1202-1209 [PMID: [25618799](#) DOI: [10.1016/j.clnu.2015.01.003](#)]
- 32 **Johnson AM**, Loftus EV. Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD. *Saudi J Gastroenterol* 2021; **27**: 183-190 [PMID: [34169900](#) DOI: [10.4103/sjg.sjg\\_30\\_21](#)]
- 33 **Harper JW**, Zisman TL. Interaction of obesity and inflammatory bowel disease. *World J Gastroenterol* 2016; **22**: 7868-7881 [PMID: [27672284](#) DOI: [10.3748/wjg.v22.i35.7868](#)]
- 34 **Reid IR**. Relationships among body mass, its components, and bone. *Bone* 2002; **31**: 547-555 [PMID: [12477567](#) DOI: [10.1016/s8756-3282\(02\)00864-5](#)]
- 35 **Khan N**, Abbas AM, Almukhtar RM, Khan A. Prevalence and predictors of low bone mineral density in males with ulcerative colitis. *J Clin Endocrinol Metab* 2013; **98**: 2368-2375 [PMID: [23596137](#) DOI: [10.1210/jc.2013-1332](#)]
- 36 **Terzoudis S**, Zavos C, Koutroubakis IE. The bone and fat connection in inflammatory bowel diseases. *Inflamm Bowel Dis* 2014; **20**: 2207-2217 [PMID: [24983981](#) DOI: [10.1097/mib.0000000000000111](#)]
- 37 **Flores A**, Burstein E, Cipher DJ, Feagins LA. Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. *Dig Dis Sci* 2015; **60**: 2436-2445 [PMID: [25799938](#) DOI: [10.1007/s10620-015-3629-5](#)]
- 38 **Bilski J**, Mazur-Bialy A, Wojcik D, Surmiak M, Magierowski M, Sliwowski Z, Pajdo R, Kwiecien S, Danielak A, Ptak-Belowska A, Brzozowski T. Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases. *Biomolecules* 2019; **9** [PMID: [31779136](#) DOI: [10.3390/biom9120780](#)]
- 39 **Fassio A**, Idolazzi L, Rossini M, Gatti D, Adami G, Giollo A, Viapiana O. The obesity paradox and osteoporosis. *Eat Weight Disord* 2018; **23**: 293-302 [PMID: [29637521](#) DOI: [10.1007/s40519-018-0505-2](#)]
- 40 **Gkastaris K**, Goulis DG, Potoupnis M, Anastasilakis AD, Kapetanios G. Obesity, osteoporosis and bone metabolism. *J Musculoskelet Neuronal Interact* 2020; **20**: 372-381 [PMID: [32877973](#) DOI: [10.1530/endoabs.63.p522](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

